EDO-1-123

EDO-1-123 is a synthetic 4-aminopyrimidine derivative and a symmetric analog of the compound A9 (2,6-dibenzyl-5-phenylpyrimidin-4-amine). Developed by researchers at Georgetown University, it was designed as a potential BRCA1-mimetic drug for the treatment of breast cancer. EDO-1-123 acts as an inhibitor of estrogen receptor 1 (ER-1) activity, aiming to block estrogen-stimulated gene expression and cell proliferation. However, in vitro assays showed it has relatively low potency compared to other analogs, with an IC50 greater than 20 uM for inhibiting E2-stimulated ERE-luciferase activity.

Other names

2,6-bis(4-chlorobenzyl)-5-(4-chlorophenyl)pyrimidin-4-amine2,6-bis(4-chlorobenzyl)-5-(4-chlorophenyl)pyrimidin-4-ylamine